Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Fryknäs, Mårten ^a   Gullbo, Joachim ^a   Wang, Xin ^b   Rickardson, Linda ^a   Jarvius, Malin ^a   Wickström, Malin ^a   Hassan, Saadia ^a   Andersson, Claes ^a   Gustafsson, Mats ^a   Westman, Gunnar ^c   Nygren, Peter ^a   Linder, Stig ^b   Larsson, Rolf ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Drug resistance; Myeloma cell lines; Primary cultures; Screening; Tubulin inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MELPHALAN; TENIPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE; VLX 40; QUINOLINOL DERIVATIVE; TUBULIN; VLX40;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOCHEMISTRY; BREAST CANCER; CELL ASSAY; CELL DEATH; CELL STRAIN U937; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG SENSITIVITY; FLUOROMETRIC CYTOTOXICITY ASSAY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENETIC ANALYSIS; HISTIOCYTIC LYMPHOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CANCER; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALE; MICROTUBULE ASSEMBLY; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIMARY CULTURE; SINGLE DRUG DOSE; T CELL LEUKEMIA; TUMOR CELL; ANIMAL; DNA MICROARRAY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FLOW CYTOMETRY; IC50; MULTIDRUG RESISTANCE; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HYDROXYQUINOLINES; INHIBITORY CONCENTRATION 50; MICE; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUBULIN;

EID: 84880974924     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-374     Document Type: Article

References (49)

1. Hait WN, Yang JM. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it. Semin Oncol 2005, 32(6 Suppl 7):S16-21.
2. Kavallaris M, Annereau JP, Barret JM. Potential mechanisms of resistance to microtubule inhibitors. Semin Oncol 2008, 35(3 Suppl 3):S22-27.
3. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997, 40(Suppl):S3-8.
4. Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?. Cancer J 2011, 17(2):89-95. 10.1097/PPO.0b013e318212dd3d, 21427552.
5. Lu H-P, Chao CCK. Cancer cells acquire resistance to anticancer drugs: an update. Biomed J 2012, 35(6):464-472.
6. Fox S, Farr-Jones S, Sopchak L, Boggs A, Nicely HW, Khoury R, Biros M. High-throughput screening: update on practices and success. J Biomol Screen 2006, 11(7):864-869. 10.1177/1087057106292473, 16973922.
7. Dhar S, Gullbo J, Nilsson K, Nygren P, Larsson R. A Nonclonogenic Cytotoxicity Assay Using Primary Cultures of Patient Tumor Cells for Anticancer Drug Screening. J Biomol Screen 1998, 3(3):207-216.
8. Hart CP. Finding the target after screening the phenotype. Drug Discov Today 2005, 10(7):513-519. 10.1016/S1359-6446(05)03415-X, 15809197.
9. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 2010, 10(4):241-253. 10.1038/nrc2820, 20300105.
10. Rickardson L, Fryknas M, Haglund C, Lovborg H, Nygren P, Gustafsson MG, Isaksson A, Larsson R. Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemother Pharmacol 2006, 58(6):749-758. 10.1007/s00280-006-0216-7, 16528529.
11. Tong AW, Lee J, Wang RM, Dalton WS, Tsuruo T, Fay JW, Stone MJ. Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody. Cancer Res 1989, 49(17):4829-4834.
12. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE. cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther 2001, 299(2):434-441.
13. Fryknas M, Dhar S, Oberg F, Rickardson L, Rydaker M, Goransson H, Gustafsson M, Pettersson U, Nygren P, Larsson R, et al. STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines. Int J Cancer 2007, 120(1):189-195. 10.1002/ijc.22291, 17072862.
14. Rickardson L, Fryknas M, Dhar S, Lovborg H, Gullbo J, Rydaker M, Nygren P, Gustafsson MG, Larsson R, Isaksson A. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer 2005, 93(4):483-492. 10.1038/sj.bjc.6602699, 2361589, 16012520.
15. Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989, 73(3):747-752.
16. Mulcahy RT, Bailey HH, Gipp JJ. Up-regulation of gamma-glutamylcyateine synthtase activity in melphalan-resitant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother Pharmacol 1994, 34:67-71. 10.1007/BF00686114, 7513621.
17. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM. Pharmacological, molecular, and cytogenetic analysis of " atypical" multidrug-resistant human leukemic cells. Cancer Res 1987, 47(20):5455-5460.
18. Mirski SE, Gerlach JH, Cole SP. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 1987, 47(10):2594-2598.
19. Botling J, Liminga G, Larsson R, Nygren P, Nilsson K. Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein. Int J Cancer 1994, 58(2):269-274. 10.1002/ijc.2910580221, 7913083.
20. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992, 50(2):177-185. 10.1002/ijc.2910500204, 1730510.
21. Csoka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 1994, 54(2):163-170. 10.1006/gyno.1994.1187, 7520407.
22. Lindhagen E, Nygren P, Larsson R. The fluorometric microculture cytotoxicity assay. Nat Protoc 2008, 3(8):1364-1369. 10.1038/nprot.2008.114, 18714304.
23. Lovborg H, Nygren P, Larsson R. Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. Mol Cancer Ther 2004, 3(5):521-526.
24. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313(5795):1929-1935. 10.1126/science.1132939, 17008526.
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-15550. 10.1073/pnas.0506580102, 1239896, 16199517.
26. Fayad W, Rickardson L, Haglund C, Olofsson MH, D'Arcy P, Larsson R, Linder S, Fryknas M. Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties. Chem Biol Drug Des 2011, 78(4):547-557. 10.1111/j.1747-0285.2011.01170.x, 21726416.
27. Friberg LE, Hassan SB, Lindhagen E, Larsson R, Karlsson MO. Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model. Eur J Pharm Sci 2005, 25(1):163-173. 10.1016/j.ejps.2005.02.006, 15854812.
28. Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Freijs A, Hansen K, Larsson R. Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats. Cancer Chemother Pharmacol 2000, 46(6):493-500. 10.1007/s002800000181, 11138463.
29. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988, 48(17):4827-4833.
30. Haglund C, Aleskog A, Nygren P, Gullbo J, Hoglund M, Wickstrom M, Larsson R, Lindhagen E. In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues. Cancer Chemother Pharmacol 2012, 69(3):697-707. 10.1007/s00280-011-1746-1, 21984220.
31. Friedman PA, Platzer EG. Interaction of anthelmintic benzimidazoles and benzimidazole derivatives with bovine brain tubulin. Biochim Biophys Acta 1978, 544(3):605-614. 10.1016/0304-4165(78)90334-3, 728472.
32. Jordan MA, Thrower D, Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci 1992, 102(Pt 3):401-416.
33. Koeller KM, Haggarty SJ, Perkins BD, Leykin I, Wong JC, Kao MC, Schreiber SL. Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation. Chem Biol 2003, 10(5):397-410. 10.1016/S1074-5521(03)00093-0, 12770822.
34. Panzer A, Joubert AM, Bianchi PC, Hamel E, Seegers JC. The effects of chelidonine on tubulin polymerisation, cell cycle progression and selected signal transmission pathways. Eur J Cell Biol 2001, 80(1):111-118. 10.1078/0171-9335-00135, 11211931.
35. Root DE, Flaherty SP, Kelley BP, Stockwell BR. Biological mechanism profiling using an annotated compound library. Chem Biol 2003, 10(9):881-892. 10.1016/j.chembiol.2003.08.009, 14522058.
36. Hamel E. Antimitotic natural products and their interactions with tubulin. Med Res Rev 1996, 16(2):207-231. 10.1002/(SICI)1098-1128(199603)16:2<207::AID-MED4>3.0.CO;2-4, 8656780.
37. Giannakakou P, Sackett D, Fojo T. Tubulin/microtubules: still a promising target for new chemotherapeutic agents. J Natl Cancer Inst 2000, 92(3):182-183. 10.1093/jnci/92.3.182, 10655426.
38. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011, 8(4):244-250. 10.1038/nrclinonc.2010.228, 21283127.
39. Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung CY, Penhallow B, Markwalder J, He L, Attar RM, Lin TA, et al. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther 2008, 7(11):3490-3498. 10.1158/1535-7163.MCT-08-0826, 19001433.
40. Yang WS, Shimada K, Delva D, Patel M, Ode E, Skouta R, Stockwell BR. Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency. ACS Med Chem Lett 2012, 3(1):35-38. 10.1021/ml200195s, 3256933, 22247791.
41. Fridborg H, Jonsson E, Nygren P, Larsson R. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer 1999, 35(3):424-432. 10.1016/S0959-8049(98)00286-X, 10448294.
42. Sabatini S, Gosetto F, Manfroni G, Tabarrini O, Kaatz GW, Patel D, Cecchetti V. Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump. J Med Chem 2011, 54(16):5722-5736. 10.1021/jm200370y, 21751791.
43. Liao CH, Chang YL, Guh JH, Kuo SC, Huang LJ, Teng CM. Effect of a potent cyclooxygenase inhibitor, 5-ethyl-4-methoxy-2-phenylquinoline (KTC-5), on human platelets. J Pharm Pharmacol 2002, 54(7):967-974. 10.1211/002235702760089090, 12162716.
44. Hadjeri M, Peiller EL, Beney C, Deka N, Lawson MA, Dumontet C, Boumendjel A. Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones. J Med Chem 2004, 47(20):4964-4970. 10.1021/jm049876x, 15369401.
45. Kuo SC, Lee HZ, Juang JP, Lin YT, Wu TS, Chang JJ, Lednicer D, Paull KD, Lin CM, Hamel E, et al. Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4′-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin. J Med Chem 1993, 36(9):1146-1156. 10.1021/jm00061a005, 8387598.
46. Li L, Wang HK, Kuo SC, Wu TS, Lednicer D, Lin CM, Hamel E, Lee KH. Antitumor agents. 150. 2′,3′,4′,5′,5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem 1994, 37(8):1126-1135. 10.1021/jm00034a010, 8164254.
47. Xia Y, Yang ZY, Xia P, Bastow KF, Nakanishi Y, Nampoothiri P, Hamel E, Brossi A, Lee KH. Antitumor agents. Part 226: synthesis and cytotoxicity of 2-phenyl-4-quinolone acetic acids and their esters. Bioorg Med Chem Lett 2003, 13(17):2891-2893. 10.1016/S0960-894X(03)00624-3, 14611851.
48. Xia Y, Yang ZY, Xia P, Bastow KF, Tachibana Y, Kuo SC, Hamel E, Hackl T, Lee KH. Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2′,3′,4′-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of antimitotic antitumor agents. J Med Chem 1998, 41(7):1155-1162. 10.1021/jm9707479, 9544215.
49. Ozgen U, Savasan S, Stout M, Buck S, Ravindranath Y. Further elucidation of mechanism of resistance to vincristine in myeloid cells: role of hypochlorous acid in degradation of vincristine by myeloperoxidase. Leukemia 2000, 14(1):47-51. 10.1038/sj.leu.2401627, 10637476.